ERBB2 and breast cancer: According to the previous study (Loibl & Gianni, 2017), pertuzumab plus trastuzumab has been shown to achieve a complete pathological response on a higher proportion of patients than trastuzumab alone, demonstrating the success of adjuvant and neoadjuvant therapy in HER2-positive early breast cancer.